These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866 [TBL] [Abstract][Full Text] [Related]
6. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000 [TBL] [Abstract][Full Text] [Related]
7. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP; Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323 [TBL] [Abstract][Full Text] [Related]
8. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions. Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J; Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472 [TBL] [Abstract][Full Text] [Related]
10. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa. González-Pinto L; Alonso-García I; Blanco-Martín T; Camacho-Zamora P; Fraile-Ribot PA; Outeda-García M; Lasarte-Monterrubio C; Guijarro-Sánchez P; Maceiras R; Moya B; Juan C; Vázquez-Ucha JC; Beceiro A; Oliver A; Bou G; Arca-Suárez J J Antimicrob Chemother; 2024 Oct; 79(10):2591-2597. PubMed ID: 39073766 [TBL] [Abstract][Full Text] [Related]
18. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain. Hernández-García M; García-Castillo M; Nieto-Torres M; Bou G; Ocampo-Sosa A; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Oliver A; Ruiz-Garbajosa P; Cantón R Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):279-296. PubMed ID: 38041722 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam. Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076 [TBL] [Abstract][Full Text] [Related]